Clinical stage novel immuno-oncology device company using proprietary nanotechnology for 'Targeted Hyperthermia Therapy' for solid cancer tumors with recent compelling first-in-human data (8/10 response for late stage otients who had failed immunotherapy). Therapy selectively kills cancer cells and in so doing causes the release of neo-antigens, engaging the immune system and causing significantly higher response rates to immunotherapy drugs in preclinical models for melanoma, colorectal cancer and triple negative breast cancer which have shown 100% response rates. Preclinical efficacy results published in Frontiers in Immunology in January with 5200 views.